Employs the firm’s multi- disciplinary systems biology strengths combined with its chemical and biomolecular engineering expertise to assess technologies relative to the competition as part of the innovation scouting and due-diligence process, including comprehensive landscaping and visualization mapping as well as benchmarking technical feasibility and quantifying performance metrics.
Applies the group’s patent analysis experience and legal knowledge to evaluate proprietary technologies. Strengths encompass conducting preliminary freedom-to-operate determinations, competitive IP landscaping, patent coverage and claim mapping. This highly complex information is communicated to clients by developing and presenting visually compelling and insightful IP materials.
Engages in discovery-driven market assessments, trend forecasting and systems analysis of therapeutics, omics-driven drug-discovery and diagnostic testing tools, among other industry-changing bioscience methods, compositions of matter and informatics software. The firm conducts emerging market-segmentation and sizing research as well as forward-looking competitive business intelligence in addition to new customer development and validation.
As an accomplished roadmapping authority, the management consultancy concentrates on biotechnology-IP-market gap analysis to assess ‘build vs. buy’ opportunities. The group quantifies new product functionality relative to unmet customer needs to enable data-driven decision-making. By developing parallel positioning scenarios and strategic commercialization plans, the firm assists driving its client’s proprietary solutions to the marketplace.
Optimize R&D, product development and other funding choices by treating these capital budgeting or multi-stage investments as Real Options for valuing the resulting operational flexibility. Probability-adjusted financial frameworks have been deployed that support the firm’s wide-ranging valuation-driven practices of strategy development and risk/reward assessments.
By leveraging its formidable financial-forecasting and profitability-analysis acumen as well as extensive corporate development and due-diligence experience, the group assists in executing licensing and collaborative alliances plus M&A transactions, including structuring, negotiating and driving to closure BD agreements. The commercial potential of emerging technologies and other growth opportunities are rigorously evaluated and subsequently guide the deal process.